Federated Hermes, Inc. Incyte Corp Transaction History

Federated Hermes, Inc.

$43.6 Billion
Q3 2024

A detailed history of Federated Hermes, Inc. transactions in Incyte Corp stock. As of the latest transaction made, Federated Hermes, Inc. holds 607,146 shares of INCY stock, worth $45 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

607,146

Previous 858,147 29.25%

Holding current value

$45 Million

Previous $52 Million 22.85%

% of portfolio

0.09%

Previous 0.13%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$57.33 - $68.61 $14.4 Million - $17.2 Million	-251,001 Reduced 29.25%	607,146 $40.1 Million
Q2 2024 Aug 08, 2024	SELL	$51.18 - $63.75 $3.95 Million - $4.92 Million	-77,223 Reduced 8.26%	858,147 $52 Million
Q1 2024 May 14, 2024	BUY	$56.55 - $66.59 $2.51 Million - $2.95 Million	44,339 Added 4.98%	935,370 $53.3 Million
Q4 2023 Jan 31, 2024	BUY	$52.16 - $64.19 $1.37 Million - $1.69 Million	26,321 Added 3.04%	891,031 $55.9 Million
Q3 2023 Nov 13, 2023	BUY	$57.77 - $65.93 $29.6 Million - $33.8 Million	512,083 Added 145.22%	864,710 $50 Million
Q2 2023 Aug 14, 2023	BUY	$60.95 - $75.51 $19.1 Million - $23.6 Million	312,733 Added 783.91%	352,627 $22 Million
Q1 2023 May 08, 2023	BUY	$70.23 - $86.01 $2.52 Million - $3.09 Million	35,937 Added 908.19%	39,894 $2.88 Million
Q4 2022 Feb 13, 2023	SELL	$67.18 - $84.11 $18,407 - $23,046	-274 Reduced 6.48%	3,957 $317,000
Q3 2022 Nov 14, 2022	SELL	$66.18 - $82.86 $1.15 Million - $1.43 Million	-17,311 Reduced 80.36%	4,231 $282,000
Q2 2022 Aug 15, 2022	SELL	$66.18 - $83.18 $13 Million - $16.3 Million	-195,789 Reduced 90.09%	21,542 $1.64 Million
Q1 2022 May 13, 2022	BUY	$66.02 - $79.71 $43,375 - $52,369	657 Added 0.3%	217,331 $17.3 Million
Q4 2021 Feb 14, 2022	BUY	$63.34 - $74.11 $8.31 Million - $9.72 Million	131,162 Added 153.38%	216,674 $15.9 Million
Q3 2021 Nov 15, 2021	BUY	$68.67 - $84.02 $5.64 Million - $6.9 Million	82,156 Added 2448.03%	85,512 $5.88 Million
Q2 2021 Aug 16, 2021	BUY	$79.87 - $87.53 $268,043 - $293,750	3,356 New	3,356 $282,000
Q1 2021 May 13, 2021	SELL	$76.02 - $100.5 $5,777 - $7,638	-76 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$80.74 - $97.7 $697,916 - $844,518	-8,644 Reduced 99.13%	76 $7,000
Q3 2020 Nov 12, 2020	SELL	$85.07 - $109.69 $160,442 - $206,875	-1,886 Reduced 17.78%	8,720 $783,000
Q2 2020 Aug 13, 2020	SELL	$74.18 - $108.93 $4.52 Million - $6.64 Million	-60,995 Reduced 85.19%	10,606 $1.1 Million
Q1 2020 May 13, 2020	SELL	$63.18 - $85.97 $13.2 Million - $18 Million	-208,986 Reduced 74.48%	71,601 $5.24 Million
Q4 2019 Feb 14, 2020	SELL	$73.04 - $95.72 $2.82 Million - $3.7 Million	-38,646 Reduced 12.11%	280,587 $24.5 Million
Q3 2019 Nov 14, 2019	SELL	$72.82 - $86.52 $733,443 - $871,429	-10,072 Reduced 3.06%	319,233 $23.7 Million
Q2 2019 Aug 14, 2019	BUY	$73.52 - $88.7 $16.1 Million - $19.4 Million	219,056 Added 198.69%	329,305 $28 Million
Q1 2019 May 10, 2019	BUY	$63.56 - $88.17 $5.69 Million - $7.89 Million	89,495 Added 431.22%	110,249 $9.48 Million
Q4 2018 Feb 13, 2019	BUY	$58.5 - $69.94 $832,806 - $995,665	14,236 Added 218.41%	20,754 $0
Q3 2018 Nov 13, 2018	SELL	$61.75 - $74.23 $69,345 - $83,360	-1,123 Reduced 14.7%	6,518 $451,000
Q2 2018 Aug 10, 2018	BUY	$60.85 - $83.98 $105,087 - $145,033	1,727 Added 29.2%	7,641 $512,000
Q1 2018 May 09, 2018	SELL	$83.06 - $100.98 $23.8 Million - $28.9 Million	-286,415 Reduced 97.98%	5,914 $493,000
Q4 2017 Feb 14, 2018	SELL	$93.56 - $116.6 $26.6 Million - $33.1 Million	-284,162 Reduced 49.29%	292,329 $0
Q3 2017 Nov 13, 2017	BUY	$109.15 - $138.27 $62.9 Million - $79.7 Million	576,491	576,491 $67.3 Million

Others Institutions Holding INCY

# of Institutions

657

Shares Held

186M

Call Options Held

714K

Put Options Held

557K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.5B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.

Account

Federated Hermes, Inc. Incyte Corp Transaction History